Last reviewed · How we verify
Placebo to TS-142
TS-142 is a drug with an unknown mechanism of action.
TS-142 is a drug with an unknown mechanism of action. Used for Phase 3 clinical trials for TS-142 are ongoing, but specific indications are not publicly available..
At a glance
| Generic name | Placebo to TS-142 |
|---|---|
| Sponsor | Taisho Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
There is limited information available on the mechanism of action of TS-142.
Approved indications
- Phase 3 clinical trials for TS-142 are ongoing, but specific indications are not publicly available.
Common side effects
Key clinical trials
- A Clinical Pharmacology Study of TS-142 in Patients with Obstructive Sleep Apnea Hypopnea. (PHASE1)
- A Phase I Study of TS-142 in Healthy Participants (Single Doses) (PHASE1)
- Early Phase 2 Clinical Study of TS-142 in Patients with Insomnia Disorder (PHASE2)
- Safety, Pharmacokinetic, and Pharmacodynamic Study of TS-142 in Healthy Subjects (PHASE2)
- A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects (PHASE1)
- A Phase I Study of TS-142 in Healthy Participants (Repeated Doses) (PHASE1)
- Late Phase II Study of TS-142 in Patients with Insomnia (PHASE2)
- A Study to Evaluate Next Day Effects of TS-142 on Driving Performance in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to TS-142 CI brief — competitive landscape report
- Placebo to TS-142 updates RSS · CI watch RSS
- Taisho Pharmaceutical Co., Ltd. portfolio CI